Biotherapy Services

Executive Summary

Biotherapy Services Limited is a UK-based biotechnology company pioneering the development of autologous cell therapies for tissue regeneration, with a primary focus on complex and chronic wound treatment. Its lead product, RAPID™ Biodynamic Haematogel, is a first-in-class, point-of-care wound treatment derived from the patient's own blood, rich in platelets and white blood cells, and classified as a medicine. The company's proprietary technology aims to address the significant unmet medical need in chronic wound management, which affects millions of patients globally and imposes a substantial economic burden on healthcare systems. By leveraging the patient's own biological components, Biotherapy's approach minimizes immunogenicity risks and offers a personalized treatment option. While the company operates in a highly competitive landscape with established players and advanced wound care technologies, its differentiated autologous platform and regulatory classification as a medicine could provide a competitive edge if clinical validation and market access are achieved. As a private company with limited disclosed funding and no commercial product yet on the market, Biotherapy Services represents an early-stage investment opportunity with potential upside contingent on successful clinical development and regulatory pathways.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2/3 Clinical Trial for RAPID™ Biodynamic Haematogel60% success
• Q3 2026Regulatory Designation (e.g., Orphan Drug or Fast Track) for RAPID™ from MHRA or EMA70% success
• TBDPartnership or Licensing Agreement with a Major Wound Care Company for European Distribution40% success